Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Shionogi Joint Venture Will Have HIV Integrase Inhibitor In Phase II

Executive Summary

GlaxoSmithKline's HIV integrase inhibitor research will advance to the clinical stage via a joint venture agreement with the Japanese firm Shionogi.

You may also be interested in...



Merck Buys Out Banyu; Will Bring “Global Perspective” To Japanese R&D

Merck's acquisition of Banyu will bring "global perspective" to Banyu's R & D efforts, Merck President-Human Health David Anstice said during a Jan. 9 conference call

Merck Buys Out Banyu; Will Bring “Global Perspective” To Japanese R&D

Merck's acquisition of Banyu will bring "global perspective" to Banyu's R & D efforts, Merck President-Human Health David Anstice said during a Jan. 9 conference call

GSK Sees New Round Of “Defensive Mergers” Ahead, CEO Says

GlaxoSmithKline sees another round of defensive mergers coming in the pharmaceutical industry, CEO J.P. Garnier declared during a securities analysts meeting in London Feb. 14

Related Content

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel